MedTrace Logo

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

NCT04007991 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2023-10-04

Study results available
· View outcomes & findings →

Summary

This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets

Conditions

  • Tourette Syndrome

Interventions

DRUG

Ecopipam

Ecopipam HCI tablets administered PO to establish 2 mg/kg/day

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • Emalex Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-28
Primary Completion
2021-09-23
Completion
2021-09-23
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04007991 on ClinicalTrials.gov